Your browser doesn't support javascript.
loading
Decreased plasma ELABELA level as a novel screening indicator for heart failure: a cohort and observational study.
Liu, Chunju; Xiong, Jianhua; Yi, Xiaoli; Song, Shanshan; Yang, Huiru; Tan, Wenting; Yang, Xiaojun; Zheng, Lixiang; Yu, Jun; Xu, Chuanming.
Afiliação
  • Liu C; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, 330004, China.
  • Xiong J; Department of Clinical Laboratory, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, 330006, China.
  • Yi X; Department of Cardiology, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, 330006, China.
  • Song S; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, 330004, China.
  • Yang H; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, 330004, China.
  • Tan W; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, 330004, China.
  • Yang X; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, 330004, China.
  • Zheng L; Department of Clinical Laboratory, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, 330006, China.
  • Yu J; College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, 330004, China.
  • Xu C; Center for Metabolic Disease Research and Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, 19140, USA.
Sci Rep ; 14(1): 11333, 2024 05 17.
Article em En | MEDLINE | ID: mdl-38760403
ABSTRACT
The predictive power of B-type natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF) is limited by its low specificity in patients with heart failure (HF). Discovery of more novel biomarkers for HF better diagnosis is necessary and urgent. ELABELA, an early endogenous ligand for the G protein-coupled receptor APJ (Apelin peptide jejunum, Apelin receptor), exhibits cardioprotective actions. However, the relationship between plasma ELABELA and cardiac function in HF patients is unclear. To evaluate plasma ELABELA level and its diagnostic value in HF patients, a total of 335 patients with or without HF were recruited for our monocentric observational study. Plasma ELABELA and Apelin levels were detected by immunoassay in all patients. Spearman correlation analysis was used to analyze the correlation between plasma ELABELA or Apelin levels and study variables. The receiver operating characteristic curves were used to access the predictive power of plasma ELABELA or Apelin levels. Plasma ELABELA levels were lower, while plasma Apelin levels were higher in HF patients than in non-HF patients. Plasma ELABELA levels were gradually decreased with increasing New York Heart Association grade or decreasing LVEF. Plasma ELABELA levels were negatively correlated with BNP, left atrial diameter, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, and left ventricular posterior wall thickness and positively correlated with LVEF in HF patients. In contrast, the correlation between plasma Apelin levels and these parameters is utterly opposite to ELABELA. The diagnostic value of ELABELA, Apelin, and LVEF for all HF patients was 0.835, 0.673, and 0.612; the sensitivity was 62.52, 66.20, and 32.97%; and the specificity was 95.92, 67.23, and 87.49%, respectively. All these parameters in HF patients with preserved ejection fraction were comparable to those in total HF patients. Overall, plasma ELABELA levels were significantly reduced and negatively correlated with cardiac function in HF patients. Decreased plasma ELABELA levels may function as a novel screening biomarker for HF. A combined assessment of BNP and ELABELA may be a good choice to increase the accuracy of the diagnosis of HF.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores / Hormônios Peptídicos / Apelina / Insuficiência Cardíaca Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores / Hormônios Peptídicos / Apelina / Insuficiência Cardíaca Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article